On Friday, Palo Alto Networks Inc (NYSE:PANW)’s shares inclined 0.62% to $184.02.
Palo Alto Networks Inc (PANW) shared research that uncovers a series of potentially state-sponsored cyberattacks targeting government and military organizations in countries throughout Southeast Asia.
Discovered by the Palo Alto Networks Unit 42 threat intelligence team and dubbed “Operation Lotus Blossom”, the attacks appear to be an attempt to gain inside information on the operation of nation-states throughout the region. The campaign dates as far back as three years and involves targets in Hong Kong, Taiwan, Vietnam, the Philippines and Indonesia.
Over 50 separate attacks have been identified in Operation Lotus Blossom. They all use a custom-built Trojan, named “Elise” to deliver highly targeted spear phishing emails and gain an initial foothold on targeted systems. Unit 42 believes the Elise malware was developed to specifically meet the unique needs of the operation, but also is being used in other non-related attacks by the adversary.
Palo Alto Networks, Inc. provides enterprise security platform to enterprises, service providers, and government entities worldwide. Its platform comprises Next-Generation Firewall that delivers application, user, and content visibility and control, in addition to protection against network-based cyber threats; and Threat Intelligence Cloud that offers central intelligence capabilities, in addition to automated delivery of preventative measures against cyber attacks.
Unum Group (NYSE:UNM)’s shares dropped -0.57% to $36.54.
Unum Group (UNM) are presently trading at $36.79. This is better than its 20-, 50-, and 100-day moving averages—as are those of the insurance firms mentioned formerly in this series.
The stock has rallied by 5.48% year-to-date and by 6.18% in just the past month. In comparison, the SPDR S&P Insurance ETF (KIE) has gained 2.87%, and the Financial Sector Select SPDR Fund (XLF) is up by 1.17%.
UNM stock is presently trading 6% off consensus price estimates of $38.31. And of the 20 analysts that cover the stock, nine rate it a “buy,” two, a “sell,” and nine, a “hold.”
According to aggregated 13F data, the stock’s top ten institutional owners actually raised their holdings by 3.6% as of March 31, 2015, with net purchases of 3,149,311 shares. The largest purchase was by Wellington Administration Group.
Unum Group, together with its auxiliaries, provides group and individual disability insurance products in the United States and the United Kingdom. The company operates through three segments: Unum US, Unum UK, and Colonial Life. It provides group long-term and short-term disability, group life, accidental death and dismemberment, individual disability, supplemental and voluntary products, and group and individual long-term care insurance products, in addition to accident, sickness and disability products, life products, and cancer and critical illness products.
At the end of Friday’s trade, AerCap Holdings N.V. (NYSE:AER)‘s shares dipped -1.40% to $46.42.
AerCap Holdings N.V (AER) declared the completion of the secondary public offering of 71,184,686 of its ordinary shares by American International Group, Inc. (the “Selling Shareholder”) at a price to the public of $49.00 per ordinary share. In connection with the underwritten offering, the Selling Shareholder also granted the underwriters a 30-day option to purchase up to an additional 10,677,702 ordinary shares. AerCap will not receive any proceeds from the sale of the ordinary shares. AerCap also accomplished its formerly declared repurchase of 15,698,588 of its ordinary shares from the Selling Shareholder for $750 million.
Citigroup and Goldman, Sachs & Co. are serving as global coordinators and joint book running managers, and J.P. Morgan, Morgan Stanley & Co. LLC and UBS Investment Bank are serving as joint book running managers for the underwritten offering.
The Company has filed a registration statement (counting a prospectus) on Form F-3 with the SEC for the underwritten offering to which this communication relates. The registration statement automatically became effective upon filing on March 31, 2015. Investors should read the accompanying prospectus dated March 31, 2015, the prospectus supplement regarding the offering dated June 3, 2015 and other documents the Company has filed with the SEC for more complete information about the Company and this offering. These documents may be obtained for free by visiting EDGAR on the SEC`s website at www.sec.gov.
AerCap Holdings N.V., an independent aircraft leasing company, engages in the leasing, financing, sale, and administration of commercial aircraft and engines. The company provides aircraft asset administration and corporate services, counting remarketing aircraft; collecting rental and maintenance payments, monitoring aircraft maintenance, monitoring and enforcing contract compliance, and accepting delivery and redelivery of aircraft; and conducting ongoing lessee financial performance reviews. Its aircraft asset administration services also comprise periodically inspecting the leased aircraft; coordinating technical modifications to aircraft to meet new lessee requirements; conducting restructurings negotiations in connection with lease defaults; repossessing aircraft; arranging and monitoring insurance coverage; registering and de-registering aircraft; arranging for aircraft and aircraft engine valuations; and providing market research services.
Idera Pharmaceuticals Inc (NASDAQ:IDRA), ended its Friday’s trading session with -2.11% loss, and closed at $3.72.
Idera Pharmaceuticals Inc (IDRA) declared that Vincent Milano, Idera’s Chief Executive Officer will will be presenting at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 24, 2015 at 12:30 p.m. Eastern Time at the St. Regis Hotel in New York City.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
